PHENOXYBENZAMINE

Posology Adults:

The usual starting dose is 10 mg daily. This may be increased by 10 mg daily until control of hypertensive episodes is achieved, or postural hypotension occurs. Usually the dosage required is 1-2 mg/kg body weight daily in two doses.

Concomitant beta-adrenergic blockade may be necessary to control tachycardia and arrythmias notably when tumours are secreting an appreciable amount of adrenaline as well as noradrenaline.

Elderly:

Use with caution: 10mg daily dose should be sufficient (see Contra- Indications and Cautions below).

Paediatric population:

There is little experience in children but, doses of 1 to 2 mg/kg daily have been used successfully. Method of Administration Oral

Side effects are generally mild and transient but may include the following adverse reactions: Not known (cannot be estimated from the available data) System organ class Frequency Adverse reactions Nervous system disorders Not known dizziness Eye disorders Not known miosis Cardiac disorders Not known compensatory tachycardia Vascular disorders Not known postural hypotension Respiratory, thoracic and mediastinal disorders Not known nasal congestion Gastrointestinal disorders Not known gastro-intestinal upset Reproductive system and breast disorders Not known inhibition of ejaculation General disorders and administration site conditions Not known lassitude Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.

It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store

Use with great caution in patients in whom a fall in blood pressure and/or tachycardia may be undesirable, such as the elderly or those with severe heart disease, congestive heart failure, cerebrovascular disease or renal damage. The mode of action should be borne in mind, if used concurrently with α-sympatho-mimetics or myocardial depressants.

Phenoxybenzamine is carcinogenic in the rat and has shown mutagenic activity in the bacterial Ames test and mouse lymphoma assay. It should only be used after very careful consideration of the risks, in patients in which alternative treatment is inappropriate.

Excipients Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose galactose malabsorption should not take this medicine.

1. Do not use in patients who have had a cerebrovascular accident; or in the recovery period (usually 3-4 weeks) after acute myocardial infarction.